Get the full picture
Sign in to uncover key details.
CC
Executive Director, Medical Affairs
MA
Director Pharmacovigilance
TS
Associate Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Zentalis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10275 Science Center Dr Ste 200, San Die...Phone Number
(212) 433-3791Website
www.zentalis.comRevenue
$26.9 MillionStock Symbol
ZNTLIndustry
About Zentalis
Zentalis Pharmaceuticals is a clinical-stage company focused on advancing azenosertib, a first-in-class WEE1 inhibitor, aimed at treating ovarian cancer and other tumor types. The company is pioneering a novel oral, non-chemotherapy, biomarker-driven approach specifically for Cyclin E1 positive platinum-resistant ovarian cancer patients. With a commitment to providing targeted therapy options, Zentalis aims to transform cancer care by offering innovative solutions where few alternatives exist. Their leadership team brings extensive experience in oncology innovation, driving the development of their focused pipeline in late-stage clinical development.Explore more
Zentalis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Zentalis
Compare insights from companies similar to Zentalis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Zentalis Tech Stack
A closer look at the technologies used by Zentalis
See more technologies
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zentalis
Sign Up For FreeTo access detailed company insights
Zentalis Pharmaceuticals is a clinical-stage company focused on advancing azenosertib, a first-in-class WEE1 inhibitor, aimed at treating ovarian cancer and other tumor types. The company is pioneering a novel oral, non-chemotherapy, biomarker-driven approach specifically for Cyclin E1 positive platinum-resistant ovarian cancer patients. With a com... Read More
